Rewind Therapeutics

TLDR

Rewind Therapeutics develops first-in-class remyelination therapeutics targeting diseases like multiple sclerosis, optic neuritis, and nerve injuries by restoring the myelin sheath.

Overview

Based in Leuven, Belgium, Rewind Therapeutics focuses on re-initiating remyelination processes to repair the myelin sheath that protects nerves in major debilitating diseases. The company leverages decades of research expertise and a strong patent estate to develop novel remyelination therapeutics, backed by top-tier life science investors including Boehringer Ingelheim Venture Fund and M-Ventures.